Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer

Prostate cancer (PCa) deaths are typically the result of metastatic castration-resistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral AR inhibitor, was approved for treating patients with mCRPC. Invariably, all PCa patients eventually develop resistance against Enz. Therefore, novel strategies...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Carcinog
Autori principali: Peak, Taylor C., Panigrahi, Gati K, Praharaj, Prakash, Su, Yixin, Shi, Lihong, Chyr, Jacqueline, Rivera-Chávez, José, Flores-Bocanegra, Laura, Singh, Ravi, Vander Griend, Donald J., Oberlies, Nicholas H., Kerr, Bethany A., Hemal, Ashok, Bitting, Rhonda L., Deep, Gagan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916724/
https://ncbi.nlm.nih.gov/pubmed/31674708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.23129
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi